Treatment with a combination of omalizumab and specific immunotherapy for severe anaphylaxis after a wasp sting

International Journal of Immunopathology and Pharmacology

Volumn 27, Issue 1, 2014, Pages 109-112

  Pałgan, Krzysztof ^a   Bartuzi, Z ^a   Gotz Zbikowska, M ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Anaphylaxis; Omalizumab; Venom specific immunotherapy

Indexed keywords

CLEMASTINE FUMARATE; DEXAMETHASONE SODIUM PHOSPHATE; HYMENOPTERA VENOM; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; OMALIZUMAB; UNCLASSIFIED DRUG; VENOMENHAL; ALLERGEN; DEXAMETHASONE; DEXAMETHASONE NATRIUM PHOSPHATE; WASP VENOM; ANTIALLERGIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; FEMALE; HUMAN; IMMUNOTHERAPY; MILD PERSISTENT ASTHMA; PEANUT; PRIORITY JOURNAL; SKIN TEST; WASP STING; ALLERGY RAPID TEST; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; DYSPNEA; GUINEA PIG; HYPOTENSION; MALE; VENOM SPECIFIC IMMUNOTHERAPY; ANIMAL; DESENSITIZATION; IMMUNOLOGY; INSECT BITE; LETTER; METHODOLOGY; TREATMENT OUTCOME; WASP;

ADULT; ANAPHYLAXIS; ANIMALS; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; INSECT BITES AND STINGS; TREATMENT OUTCOME; WASP VENOMS; WASPS;

EID: 84900525966     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201402700114     Document Type: Article

References (14)

1. Vetter RS, Visscher PK, Camazine S. Mass envenomation by honey bees and wasps. West J Med 1999; 170:223-27. (Pubitemid 32612758)
2. Przybilla B, Ruëff F. Insect stings. Clinical features and management. Dtsch Arztebl Int 2012; 109:238-48.
3. Boyle RJ, Elremeli M, Hockenhull J, Cherry MG, Bulsara MK, Daniels M, Oude Elberink JN. Venomimmunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev 2012; 17;10:CD008838. doi: 10.1002/14651858.CD008838.pub2.
4. Galera C, Soohun N, Zankar N, Caimmi S, Gallen C, Demoly P. Severe anaphylaxis to bee venomimmunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol. 2009; 19:225-29.
5. Müller UR. Insect allergy. Clinical picture, diagnosis and treatment. 1990. Ed. Gustav Fisher, Stuttgart-New York.
6. Bilò BM, Bonifazi F. Hymenoptera venom immunotherapy. Immunotherapy 2011; 3:229-46. doi: 10.2217/imt.10.88.
7. Golden DBK. Insect sting anaphylaxis. Immunol Allergy Clin North Am 2007; 27:261-69.
8. Bilò MB, Antonicelli L, Bonifazi F. Honeybee venom immunotherapy: certainties and pitfalls. Immunotherapy 2012; 4:1153-66.
9. Ruëff F, Przybilla B, Biló MB, et al Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. European Academy of Allergy and Clinical Immunology Interest Group. J Allergy Clin Immunol 2010; 126:105-11.
10. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med 2012; 18:693-704.
11. Shankar T, Petrov AA. Omalizumab and hypersensitivity reactions. Curr Opin Allergy Clin Immunol 2013; 13:19-24.
12. Lowe PJ. Renard D. Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE. Br J Clin Pharmacol 2011; 72:306-20.
13. Kopp MV. Omalizumab: Anti-IgE therapy in allergy. Curr Allergy Asthma Rep 2011; 11:101-6.
14. Belliveau PP. Omalizumab: A Monoclonal anti-IgE antibody. Med Gen Med 2005; 7:27-39.